Medicare Part D coverage · brimonidine tartrate · RxCUI 861206
brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan]
Per the CMS 2026 Part D formulary file, brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] is covered by 1,273 Medicare Part D plans (25.2% of enrollable products), averaging Tier 2.9, with prior authorization required on 0% of covering formularies.
- 25.2%
- Plan coverage
- 1,273
- Plans covering
- T2.9
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan]
Per the CMS 2026 Part D formulary file, brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] (RxNorm concept RXCUI 861206, generic name brimonidine tartrate) appears on 30 distinct formulary files spanning 1,273 Medicare Part D plan offerings - 25.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 3, with a cross-plan average of Tier 2.9.
Real-world access to brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 6.7% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 573,214 Part D beneficiaries filled brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] in 2023, with total plan-and-beneficiary spending of $88,900,177 and an average per-beneficiary annual cost of $155.09. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] today.
Coverage Details
- Formularies covering
- 30
- Plans covering
- 1,273
- Coverage rate
- 25.2%
- Tier range
- Tier 1 – Tier 3
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 6.7% of formularies
2023 Medicare Spending
- Beneficiaries
- 573,214
- Total spending
- $88,900,177
- Avg per beneficiary
- $155.09
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan]
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T3 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T3 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan]
98 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Sentara Community Complete Select (HMO D-SNP) | Sentara Health Plans | T1 | No | $0 | VA |
| Sentara Community Complete (HMO D-SNP) | Sentara Health Plans | T1 | No | $0 | VA |
| Hamaspik Medicare Choice (HMO D-SNP) | Hamaspik, Inc. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | Hamaspik, Inc. | T1 | No | $34.50 | NY |
| UHC Dual Complete IA-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T3 | No | $0 | IA |
| UHC Dual Complete MO-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T3 | No | $0 | MO |
| UHC Dual Complete NE-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T3 | No | $0 | NE |
| UHC Dual Complete KS-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T3 | No | $0 | KS |
| UHC Dual Complete MO-S3 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T3 | No | $0 | MO |
| UHC Dual Complete KS-Q1 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T3 | No | $0 | KS |
| UHC Dual Complete TN-S001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T3 | No | $0 | TN |
| UHC Dual Complete TN-Y001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T3 | No | $0 | TN |
| UHC Dual Complete TN-Y2 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T3 | No | $0 | TN |
| AARP Medicare Advantage from UHC MI-0001 (PPO) | Unitedhealthcare Insurance Company | T3 | No | $0 | MI |
| UHC Dual Complete NM-Y1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T3 | No | $0 | NM |
| UHC Dual Complete NM-S1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T3 | No | $0 | NM |
| UHC Dual Complete NM-V1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T3 | No | $0 | NM |
| UHC Dual Complete AZ-S001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T3 | No | $0 | AZ |
| UHC Dual Complete AZ-Y001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T3 | No | $0 | AZ |
| UHC Dual Complete VA-Y4 (PPO D-SNP) | Care Improvement Plus South Central Insurance Co. | T3 | No | $0 | VA |
Show the next 30 plans
Showing top 50 of 98 plans.
Frequently Asked Questions
Is brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] covered by Medicare Part D?
Yes, brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] is covered by 1,273 Medicare Part D plans (25.2% of all Part D formularies).
What tier is brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] on Medicare Part D plans?
brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] averages Tier 2.9 across Part D plans, ranging from Tier 1 to Tier 3.
Does brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] require prior authorization?
0% of Part D formularies require prior authorization for brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan]. Step therapy: 0%. Quantity limits: 6.7%.
How much does Medicare spend on brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan]?
In 2023, total Medicare Part D spending on brimonidine tartrate 1 MG/ML Ophthalmic Solution [Alphagan] was $88,900,177, covering 573,214 beneficiaries. The average spend per beneficiary was $155.09.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA